Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling EraPlain-Language Summary

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling EraPlain-Language Summary

Rationale & Objective: Since the change in erythropoiesis-stimulating agent (ESA) labeling and bundling of dialysis services in the United States, few studies have addressed the clinical importance of ESA hyporesponsiveness and none have considered health care resource use in this population...

Full description

Bibliographic Details
Main Authors: Borut Cizman, Helen T. Smith, Rodrigo Refoios Camejo, Linda Casillas, Harjeet Dhillon, Fan Mu, Eric Wu, Jipan Xie, Peter Zuckerman, Daniel Coyne
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Kidney Medicine
Subjects:
ESA hyporesponsiveness
erythropoietin
health care resource utilization
hemodialysis
USRDS Medicare
anemia of chronic kidney disease
Online Access:http://www.sciencedirect.com/science/article/pii/S259005952030162X

Internet

http://www.sciencedirect.com/science/article/pii/S259005952030162X

Similar Items